Leerink lowered the firm’s price target on Guardant Health to $50 from $60 and keeps an Outperform rating on the shares ahead of Q3 earnings, as the firm previews key debates for companies across its Life Science Tools and Diagnostics coverage. Leerink sees three major themes, namely the timing of recovery in core pharma/biotech end-markets, China still weak but stable sequentially, and possible weakness in academic end-market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health publishes SCRUM-Japan GOZILA study results
- Exact Sciences added to ‘Tactical Outperform List’ at Evercore ISI
- Guardant Health, Italy’s Policlinico Gemelli team on liquid biopsy testing
- Guardant Health management to meet with Craig-Hallum
- Boeing’s Starliner to return without astronauts: Morning Buzz